Skip to main content
. 2020 Dec;11(6):1431–1439. doi: 10.21037/jgo-20-344

Figure 2.

Figure 2

OS was irrelated with CLDN18.2 expression. (A) OS in CLDN18.2 positive patients and negative patients, median OS (mOS) was 17.0 months compared to 9.0 months, P=0.107. (B) mOS was 15.9 months in patients who had CLDN18.2 expression in ≥40% of tumor cells and 20.3 months in patients who had CLDN18.2 expression in <40% of tumor cells, P=0.128. (C) mOS was 16.0 months in patients who had CLDN18.2 expression in ≥70% of tumor cells and 17.5 months in patients who had CLDN18.2 expression in <70% of tumor cells, P=0.694. (D) mOS was 16.9 months in patients who had CLDN18.2 expression in ≥90% of tumor cells and 17.0 months in patients who had CLDN18.2 expression in <90% of tumor cells, P=0.816. OS, overall survival.